Xtl Biopharmaceuticals (XTLB) Asset Writedowns and Impairment (2014)

Xtl Biopharmaceuticals (XTLB) posted quarterly Asset Writedowns and Impairment of $1000.0 for Q4 2014, down 99.29% on a QoQ basis from $141000.0 in Q2 2014.

Xtl Biopharmaceuticals (XTLB) Asset Writedowns and Impairment (2014) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Asset Writedowns and Impairment for 1 consecutive years, with $1000.0 the latest figure, recorded in Q4 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,801.52 Bn 66,801.23 Bn -
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.65 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.85 Bn 61.09 Bn 3.31 Bn
7 Belite Bio 63.06 Bn 63.06 Bn -
8 Argenx Se 55.74 Bn 50.56 Bn 1.41 Bn
9 Revolution Medicines 37.48 Bn 37.48 Bn -
10 Xtl Biopharmaceuticals 2.58 Bn 2.58 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2014 1,000.00
Dec 31, 2014 1,000.00
Jun 30, 2014 141,000.00
Jun 30, 2014 141,000.00